Clincosm LogoSign in Get a demo

Thiol-disulfide Homeostasis in Patients With Ovarian Cancer

Sponsor
Tepecik Training and Research Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05011539
Collaborator
(none)
128
Enrollment
1
Location
9.8
Anticipated Duration (Months)
13.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Ovarian cancer is the third most common after endometrial and cervical cancer in societies with a high standard of living; It is the second most common type of gynecological cancer after cervical cancer in societies with a low standard of living, and it is also the deadliest among gynecological cancers. Dynamic thiol-disulfide homeostasis is an antioxidant system that minimizes oxidative damage and prevents cell damage. In the presence of oxidative stress, the thiol groups combine to form the disulfide structure, and when the oxidative stress condition is over, they are separated into thiol groups again. This homeostasis is impaired in conditions that cause oxidative processes such as diabetes, cardiovascular diseases, cancers, rheumatoid arthritis, and chronic kidney failure. This can be determined by measuring the total thiol and native thiol levels. Likewise, the level of ischemia modified albumin increases in the case of oxidative stress. There are studies on this homeostasis in the literature on many types of cancer; There are studies on endometrial cancer and cervical cancer, which are gynecological cancers In this study, the usability of these tests together with other diagnostic tests in the diagnosis of ovarian cancer will be evaluated.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    128 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Thiol-disulfide Homeostasis in Patients With Ovarian Cancer
    Actual Study Start Date :
    Apr 9, 2021
    Anticipated Primary Completion Date :
    Jan 1, 2022
    Anticipated Study Completion Date :
    Feb 1, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    Ovarian cancer

    The patients with ovarian cancer
    Control group

    Outcome Measures

    Primary Outcome Measures

    1. thiol - disulfide levels [April 2021 - January 2021]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Histopathological diagnosis of ovarian cancer
    Exclusion Criteria:

    • Having an acute or chronic disease that will cause oxidative stress

    • Using alcohol/cigarettes/drugs

    • Using antioxidant agents (such as vitamins A, C, E)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Izmir Tepecik Training and Research Hospital İzmir Konak Turkey 35020

    Sponsors and Collaborators

    • Tepecik Training and Research Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Alaattin Karabulut, Medical Doctor, Tepecik Training and Research Hospital
    ClinicalTrials.gov Identifier:
    NCT05011539
    Other Study ID Numbers:
    • TepecikTRH-AKarabulut-001
    First Posted:
    Aug 18, 2021
    Last Update Posted:
    Aug 18, 2021
    Last Verified:
    Aug 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Ovarian Neoplasms
    Carcinoma, Ovarian Epithelial

    Study Results

    No Results Posted as of Aug 18, 2021